ClinicalTrials.gg
Not yet recruitingNCT07230158Updated Nov 17, 2025

Transcranial Alternating Current Stimulation for Patients With Mild Alzheimer's Disease II (TRANSFORM-AD II)

An interventional study of sham stimulation and transcranial alternating current stimulation in Alzheimer Disease, sponsored by Xuanwu Hospital, Beijing. Not yet recruiting at 1 site in China. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by Xuanwu Hospital, Beijing · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
50 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 26 studies in Alzheimer Disease by Xuanwu Hospital, Beijing — 19 open to participants now, 20 under way, 1 of them phase 3. Alzheimer Disease · Xuanwu Hospital, Beijing.

Planned enrollment
5th of 19
160 · median 40
Started
2025
with 7 others
No phase
13 of 26
8 open now
Primary completion
2027-09
later than 11 of 19 live
Registered
19th of 26
by date

Among the 26 studies in Alzheimer Disease by Xuanwu Hospital, Beijing, this one is the 5th largest by planned enrollment of the 19 interventional ones that give a count, is one of 8 that started in 2025, is one of 13 with no phase, reaches primary completion later than 11 of the 19 other live ones, and was the 19th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

19 of the 26 studies in Alzheimer Disease by Xuanwu Hospital, Beijing are open now, in 1 country. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 50 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Alzheimer Disease by Xuanwu Hospital, Beijing, or all of them as a file.
02

Study summary

The goal of this study is to explore the efficacy and safety of transcranial alternating current stimulation (tACS) in patients with amnestic mild cognitive impairment due to Alzheimer's disease (AD-aMCI) and patients with mild Alzheimer's disease dementia (AD-MD). The study will recruit 160 individuals with mild cognitive impairment with evidence of amyloid plaques in the brain through Positron Emission Tomography (PET) imaging. Participants will undergo baseline cognitive assessment, structural and functional MRI characterization, PiB-PET, and EEG measurement. The participants will be randomized to either a tACS group or a sham stimulation group. At the end of the intervention, all subjects will repeat the baseline assessments.

Read the detailed description

Background In our previous study, we applied 40 Hz transcranial alternating current stimulation (tACS) to patients with mild Alzheimer's disease (AD), and the results demonstrated significant improvements in cognitive function. Building upon these findings, the present study applies a combined high-gamma (77.5 Hz) and low-gamma (40 Hz) tACS protocol to target patients with amnestic mild cognitive impairment due to Alzheimer's disease (AD-aMCI) and those with mild Alzheimer's disease dementia (AD-MD). This dual-frequency stimulation aims to enhance cognitive performance through synergistic gamma-band modulation and to explore its underlying therapeutic mechanisms.

Methods The TRANSFORM-AD II trial is a double-blind, randomized controlled study that will enroll 160 participants diagnosed with AD-aMCI or AD-MD. Eligible participants must meet at least one of the following criteria: positive amyloid positron emission tomography (PET), decreased cerebrospinal fluid (CSF) amyloid-β levels, or elevated plasma phosphorylated tau 217 (p-Tau217) levels. Participants will be randomly assigned to either the active stimulation group (77.5 Hz + 40 Hz tACS) or the sham stimulation group. Both groups will receive 60 one-hour sessions over an 8-week period. Outcome measures will be assessed at baseline and immediately after the intervention.

The primary outcome is global cognitive function, measured using the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog 13).

Secondary outcomes include changes in other neuropsychological test scores, multimodal magnetic resonance imaging (MRI) metrics, and resting-state as well as task-related electroencephalography (EEG) indicators.

Results This trial is currently ongoing, with recruitment expected to be completed by June 2026.

Conclusion This study will evaluate the efficacy and safety of combined 77.5 Hz and 40 Hz tACS in patients with AD-related aMCI and mild AD dementia. Furthermore, it will investigate potential therapeutic mechanisms using multimodal MRI to assess brain structure and function, and EEG to characterize both resting-state and task-related neural activity patterns.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged 50-90 years, either inpatients or outpatients;
  2. Meeting the NIA-AA clinical diagnostic criteria established by the 2018 National Institute on Aging and Alzheimer's Association (NIA-AA) group for AD-related amnestic mild cognitive impairment (a-MCI) or AD-related mild dementia;
  3. Neuropsychological evaluation with score of 18-26 and CDR score of 0.5 or 1;
  4. Positive amyloid PET, or decreased amyloid levels in cerebrospinal fluid, or elevated serum phosphorylated Tau217 protein;
  5. Able to communicate proficiently in Chinese (non-illiterate);
  6. If currently receiving cholinesterase inhibitor treatment (such as donepezil or rivastigmine), the current treatment dose must be stable (i.e., fixed dose for at least 6 consecutive weeks), with no planned dose adjustments during the study observation period;
  7. Signed form.

Exclusion criteria

Exclusion Criteria:

  1. Sudden onset;
  2. Early focal neurological manifestations or extrapyramidal manifestations;
  3. Systemic diseases that may cause cognitive impairment (such as liver or kidney insufficiency, endocrine diseases, or vitamin deficiency), or neurological diseases such as brain trauma, epilepsy, encephalitis, or normal pressure hydrocephalus;
  4. Meeting criteria for depression or schizophrenia;
  5. Ongoing drug treatments that may affect baseline or follow-up assessments;
  6. for MRI or neurophysiological examinations, such as cardiac pacemakers, cardiac defibrillators, implanted electronic systems, vascular clips, mechanical heart valves, or cochlear implants;
  7. Cranial MRI showing ischemic lesions meeting NINCDS-AIREN criteria.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    tACS stimulation group

    NEXALIN ADI transcranial alternating current stimulator

    Device: transcranial alternating current stimulation

  • Sham comparator
    sham stimulation group

    Sham stimulator provided by NEXALIN company

    Device: sham stimulation

Interventions

  • Devicesham stimulation

    Electrodes will also be placed on the patient's forehead and behind both ears. The sham stimulator is identical in appearance to the true stimulator. Neither participants nor operators can distinguish whether the stimulator is real based on its appearance or the patient's sensations. However, when the device is activated, no current flows through the electrodes. Participants in this group will receive sham stimulation with 60 one-hour sessions within 8 weeks.

  • Devicetranscranial alternating current stimulation

    The alternating current is delivered through medical-grade conductive electrode pads manufactured specifically for Nexalin technology. The electrode pads are placed on the forehead and behind both ears, and are connected to the Nexalin device with thin cables. The intervention will be conducted with a tACS device: 50 minutes of high-gamma frequency (77.5 Hz) combined with 10 minutes of low-gamma frequency (40 Hz), with a peak-to-peak amplitude of 15 mA. A total of 60 one-hour sessions will be completed within 8 weeks.

06

What researchers measure

Primary outcomes

  1. Change in Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-cog, 13-items version).

    ADAS-cog 13 scale ranges from 0 to 85, and higher value represents a worse outcome. This study will use ADAS-cog to assess changes in the global cognitive function after intervention.

    Time frame: up to 8 weeks (end of intervention)

Secondary outcomes

  1. Change in MRI brain connectivity

    Functional MRI and DTI will be used to measure the connectivity of different ROIs, and the intervention effect will be evaluated by assessing changes in connectivity indicators before and after the intervention.

    Time frame: up to 8 weeks (end of intervention)

  2. Temporal lobe cross-frequency coupling dynamics and intervention effects

    This study aims to evaluate the dynamic changes in cross-frequency coupling (CFC) indices within the temporal lobe across different time points following intervention. By analyzing phase-amplitude coupling between distinct frequency bands, the study seeks to characterize alterations in α-γ and θ-γ coupling patterns in individuals with migraine and epilepsy. The findings will help elucidate the role of temporal lobe functional connectivity in disease progression and in the modulation of non-pain symptoms.

    Time frame: Up to 8 weeks (end of intervention)

  3. Changes in brain volume and brain function

    Structural and functional MRI will be used to measure brain structure and brain function

    Time frame: up to 8 weeks (end of intervention)

  4. Change in Mini-mental State Examination

    Mini-mental State Examination (MMSE) will be used to evaluate the general cognitive function. MMSE ranges from 0 to 30, and higher value represents a better outcome.

    Time frame: up to 8 weeks (end of intervention)

  5. Change in Montreal Cognitive Assessment

    Montreal Cognitive Assessment (MoCA) will be used to evaluate the general cognitive function. MoCA ranges from 0 to 30, and higher value represents a better outcome.

    Time frame: up to 8 weeks (end of intervention)

  6. Change in Clinical Dementia Rating Scale sum of the boxes

    Clinical Dementia Rating Scale sum of the boxes (CDR-SB) will be used to evaluate the general cognitive function. CDR-SB ranges from 0 to 18, and higher value represents a worse outcome.

    Time frame: up to 8 weeks (end of intervention)

  7. Change in memory function

    WHO-UCLA Auditory Verbal Learning Test will be used to assess memory function. It ranges from 0 to 45, and higher values represent better outcomes. In addition, task-related EEG will be conducted during memory tasks to further evaluate memory-related neural activity.

    Time frame: up to 8 weeks (end of intervention)

  8. Change in Digit span forward

    Digit span will be used to assess attention. It ranges from 3 to 10, and higher value represents a better outcome.

    Time frame: up to 8 weeks (end of intervention)

  9. Change in Digit span backward

    Digit span backward will be used to assess executive function. It ranges from 2 to 8, and higher value represents a better outcome.

    Time frame: up to 8 weeks (end of intervention)

  10. Change in Trail Making Test

    Trail-Making Test B minus A score will be used to assess executive function. Trail-Making Test B minus A ranges from -150 to 300, higher value represents a worse outcome.

    Time frame: up to 8 weeks (end of intervention)

  11. Change in Boston Naming Test

    Boston Naming Test will be used to assess language function. It ranges from 0 to 30, and higher value represents a better outcome.

    Time frame: up to 8 weeks (end of intervention)

  12. Change in Neuropsychiatric Inventory (NPI)

    The Neuropsychiatric Inventory will be used to measure neuropsychiatric symptoms. It ranges from 0 to 144, and higher value represents a worse outcome.

    Time frame: up to 8 weeks (end of intervention)

  13. Change in Geriatric Depression Scale (GDS)

    The Geriatric Depression Scale will be used to measure neuropsychiatric symptoms. It ranges from 0 to 30, and higher value represents a worse outcome.

    Time frame: up to 8 weeks (end of intervention)

  14. Change in Activities of Daily Living

    Activities of Daily Living (ADL) scale will be used to assess the change of life quality. It ranges from 20 to 80. The "20" represents normal life ability and the higher score presents the worse life ability.

    Time frame: up to 8 weeks (end of intervention)

  15. Side-effects of tACS

    Adverse Events as a result of tACS stimulation will be reported.

    Time frame: up to 8 weeks (end of intervention)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Study Protocol, Statistical Analysis Plan (SAP), Informed Consent Form (ICF), Clinical Study Report (CSR), Analytic Code

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: 2025.9.20-2027.9.20

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2025; primary completion for Sep 2027, 21 months later.

Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 21 months is below that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2025
First posted
Nov 17, 2025
StartEst.
Nov 30, 2025
Primary completionEst.
Sep 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07230158
Collaborators
Beijing Geriatric Hospital, The First Affiliated Hospital of Zhengzhou University, First Affiliated Hospital of Chongqing Medical University, The Fifth People's Hospital of Datong
Responsible party
Sponsor
First posted
Nov 17, 2025
Start date
Nov 30, 2025 (estimated)
Primary completion
Sep 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Nov 17, 2025

Study contacts

Yi Tang, M.D., Ph.D
Contact
tangyixw@vip.163.com
00861083199456
Yi Xing, M.D.
Contact
xingyi_211@163.com
008613269627589
Yi Tang, M.D., Ph.D.
principal investigator · Xuanwu Hospital, Beijing

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion